Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | LMY-920 |
| Trade Name | |
| Synonyms | LMY920|LMY 920|Autologous BAFF-expressing CAR T Cells |
| Drug Descriptions |
LMY-920 comprises autologous CD4- and CD8-positive T-lymphocytes engineered to express a chimeric antigen receptor (CAR) containing the B-cell activating factor (BAFF) ligand, which potentially induce cytotoxicity against tumor cells expressing BAFF-R (TNFRSF13C), BCMA (TNFRSF17), or TACI (TNFRSF13B) (NCI Drug Dictionary). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | C187330 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Cyclophosphamide + Fludarabine + LMY-920 + Obinutuzumab | Cyclophosphamide Fludarabine LMY-920 Obinutuzumab | 0 | 1 |
| LMY-920 | LMY-920 | 0 | 2 |